CO2019004798A2 - Formulation of pharmaceutical complex comprising amlodipine, losartan and chlorthalidone - Google Patents

Formulation of pharmaceutical complex comprising amlodipine, losartan and chlorthalidone

Info

Publication number
CO2019004798A2
CO2019004798A2 CONC2019/0004798A CO2019004798A CO2019004798A2 CO 2019004798 A2 CO2019004798 A2 CO 2019004798A2 CO 2019004798 A CO2019004798 A CO 2019004798A CO 2019004798 A2 CO2019004798 A2 CO 2019004798A2
Authority
CO
Colombia
Prior art keywords
chlorthalidone
losartan
amlodipine
formulation
pharmaceutical complex
Prior art date
Application number
CONC2019/0004798A
Other languages
Spanish (es)
Inventor
Ho Taek Im
Jae Hyun Park
Jong Soo Woo
Yong Il Kim
Hyuk Jun Cho
Sol Ee Lim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62076324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019004798(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO2019004798A2 publication Critical patent/CO2019004798A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una formulación de complejo farmacéutica que incluye amlodipina, losartán y clortalidona como ingredientes activos. La formulación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y clortalidona como ingredientes activos presenta excelentes características de disolución de los ingredientes activos, y tiene una alta uniformidad de contenido y estabilidad térmica. Por lo tanto, la formulación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que tiene una excelente calidad y estabilidad térmica.The present invention relates to a pharmaceutical complex formulation that includes amlodipine, losartan and chlorthalidone as active ingredients. The pharmaceutical complex formulation of the present invention that includes amlodipine, losartan and chlorthalidone as active ingredients has excellent dissolution characteristics of the active ingredients, and has a high uniformity of content and thermal stability. Therefore, the complex formulation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has excellent quality and thermal stability.

CONC2019/0004798A 2016-11-03 2019-05-10 Formulation of pharmaceutical complex comprising amlodipine, losartan and chlorthalidone CO2019004798A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160145518A KR101910902B1 (en) 2016-11-03 2016-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
PCT/KR2017/012396 WO2018084627A2 (en) 2016-11-03 2017-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
CO2019004798A2 true CO2019004798A2 (en) 2019-05-21

Family

ID=62076324

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0004798A CO2019004798A2 (en) 2016-11-03 2019-05-10 Formulation of pharmaceutical complex comprising amlodipine, losartan and chlorthalidone

Country Status (12)

Country Link
KR (1) KR101910902B1 (en)
CO (1) CO2019004798A2 (en)
CR (1) CR20190264A (en)
DO (1) DOP2019000093A (en)
EA (1) EA201991107A1 (en)
EC (1) ECSP19038749A (en)
MX (1) MX2019005178A (en)
NI (1) NI201900046A (en)
PH (1) PH12019500778A1 (en)
SG (1) SG11201903145TA (en)
WO (1) WO2018084627A2 (en)
ZA (1) ZA201902718B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143914A (en) * 2019-06-17 2020-12-28 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt
KR20210074428A (en) 2019-12-11 2021-06-22 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20210152943A (en) 2020-06-09 2021-12-16 한미약품 주식회사 Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet
CR20220664A (en) * 2020-06-09 2023-03-03 Hanmi Pharm Ind Co Ltd COMPLEX PHARMACEUTICAL PREPARATION, TO PREVENT OR TREAT CARDIOVASCULAR DISEASES, WHICH COMPRISES AMLODIPINE, LOSARTAN AND CHLORTALIDONE IN A SINGLE-LAYER TABLET
TW202241409A (en) * 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 New formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine for the oral administration
CN114705785B (en) * 2022-04-21 2023-11-07 厦门泓益检测有限公司 Method for detecting chlorophthalic acid in vegetable oil

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298351T5 (en) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG METHOD FOR PRODUCING A TWO-LAYER PHARMACEUTICAL TABLET THAT INCLUDES TELMISARTAN AND HYDROCLOROTIAZIDA.
JP2009513543A (en) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Chlorthalidone combination
KR100924236B1 (en) * 2009-06-23 2009-10-29 충남대학교산학협력단 Methods and apparatus for preparing ultra-fine particles with narrow particle size distribution
KR20150079373A (en) * 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
KR101914930B1 (en) * 2015-03-31 2018-11-05 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Also Published As

Publication number Publication date
WO2018084627A2 (en) 2018-05-11
WO2018084627A3 (en) 2018-07-26
NI201900046A (en) 2019-10-11
EA201991107A1 (en) 2019-09-30
CR20190264A (en) 2019-08-26
ECSP19038749A (en) 2019-06-30
MX2019005178A (en) 2019-08-05
KR20180049510A (en) 2018-05-11
KR101910902B1 (en) 2018-10-24
ZA201902718B (en) 2020-08-26
PH12019500778A1 (en) 2019-07-24
DOP2019000093A (en) 2019-09-30
SG11201903145TA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CO2019004798A2 (en) Formulation of pharmaceutical complex comprising amlodipine, losartan and chlorthalidone
AU2018389797B2 (en) Packaged modified release gamma-hydroxybutyrate formulations having improved stability
CL2017003459A1 (en) Cyclic sulfamoylarylamide derivatives and their use as medicines for the treatment of hepatitis b.
CL2016002269A1 (en) Allosteric modulators of the hepatitis core protein b.
CL2018000684A1 (en) Modulators of hepatitis core protein b.
CL2018000542A1 (en) New phenoxymethyl derivatives.
BR112018010720A2 (en) apelin receptor agonists and methods of use
BR112018003110A2 (en) therapeutic nanoparticles comprising a therapeutic agent and methods of manufacturing and using them
BR112016023422A8 (en) spray-dried dispersion, pharmaceutical composition and its uses, kit and tablet
CL2018001298A1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CL2015002897A1 (en) Bace1 inhibitors
CL2017001964A1 (en) Encapsulation of high power active agents.
CU20180035A7 (en) ATTENDED INFLUENZA VECTORS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
CO2018002428A2 (en) Selected amide of gamma-hydroxyiburic acid and uses thereof in the treatment of alcohol abuse
UY36595A (en) COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTÁN AND CLORTALIDONA
DOP2019000015A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
ECSP19000169A (en) PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
CO2018011420A2 (en) Liquid phosphaplatin formulations
CU20170134A7 (en) 2-THIOPIRIMIDINONES
CO2019004796A2 (en) Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin
MX2020004731A (en) Ezh2 inhibitor combination therapies.
EA201891848A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS
UY35956A (en) FORMULATION OF ATAZANAVIR AND COBICISTAT FOR THE TREATMENT OF HIV
UA93885U (en) MEDICINES IN THE FORM OF PESARY FOR THE TREATMENT OF GYNECOLOGICAL DISEASES